NanJing Pharmaceutical Company Limited

Equities

600713

CNE000000KV1

Pharmaceuticals

End-of-day quote Shanghai S.E. 03:30:00 14/05/2024 am IST 5-day change 1st Jan Change
4.92 CNY +0.82% Intraday chart for NanJing Pharmaceutical Company Limited +0.20% +1.65%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NanJing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
NanJing Medical Plans to Issue Up to 6 Billion Yuan in Ultra Short-Term Bonds MT
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
NanJing Pharmaceutical Company Limited(XSSC:600713) added to S&P Global BMI Index CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
NanJing Pharmaceutical Company Limited entered into Framework Agreement to acquire 55% stake in Suzhou Tianqing Xingwei Pharmaceutical Co., Ltd., a 55% stake in Zhejiang Tianqing Zhongwei Pharmaceutical Co., Ltd., and a 100% of Lianyungang Chia Tai-Tianqing Pharmaceutical Co., Ltd. CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
NanJing Medical’s Controlling Shareholder Boosts Stake to 44.2% For $158 Million MT
NanJing Pharmaceutical Company Limited announced that it has received CNY 997.999997 million in funding from Nanjing XinGong Investment Group Co., Ltd CI
Sichuan Luyan Pharmaceutical Co., Ltd. agreed to acquire Sichuan Yatong Pharmaceutical Co., Ltd. from NanJing Pharmaceutical Company Limited for CNY 19.9 million. CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
NanJing Pharmaceutical Company Limited announced that it expects to receive CNY 999.999998 million in funding from Nanjing XinGong Investment Group Co., Ltd CI
Nanjing Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Nanjing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Nanjing Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Nanjing Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2020 CI
NanJing Pharmaceutical Company Limited Declares Distribution for 2019, Payable on June 24, 2020 CI
Nanjing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Nanjing Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Chart NanJing Pharmaceutical Company Limited
More charts
NanJing Pharmaceutical Company Limited is a China-based company principally engaged in the pharmaceutical distribution business. The Company's principal businesses include the pharmaceutical wholesale, pharmaceutical retail, pharmaceutical-Internet + business, as well as the pharmaceutical third-party logistics services. The Company mainly conducts its business in domestic market.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 600713 Stock
  4. News NanJing Pharmaceutical Company Limited
  5. NanJing Medical Plans to Issue Up to 6 Billion Yuan in Ultra Short-Term Bonds
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW